TMC

targeted molecules focuses its discovery and development efforts in the field of selective adhesion molecule inhibitors (SAMI). SAMI drugs have already been approved for use in the treatment of acute cardiac conditions and psoriasis, and additional agents are in clinical development for a wide range of indications including multiple sclerosis, Crohn’s Disease, rheumatoid arthritis, and cancer. TMC uses its proprietary technology and extensive expertise in this field to identify novel SAMI antibodies for development

Proprietary Technology
TMC has developed a novel discovery platform that utilizes in vivo models to screen complex libraries of candidate molecules and identify those that bind to receptors located in the vascular system. This technology can be applied to all forms of protein drugs including peptides and single chain antibodies, and is particularly well suited to the discovery on novel SAMI drugs.

Careers:

TMC offers motivated individuals the opportunity to join in the excitement of an emerging biopharmaceutical company. We are located in San Diego, a thriving Biotech Community located on the Southern Californian coast. In addition to a stimulating scientific environment, TMC offers a competitive salary, stock options, and a comprehensive benefits program including a 401(k) plan. TMC is an equal opportunity employer.

Contact:

3030 Bunker Hill St. Suite 100
San Diego, CA 92109
U.S.A. Phone: 858-777-2800
Fax: 858-777-2810

web : www.targetedmolecules.com